The global anticoagulants market size was estimated at USD 35,957.0 million in 2024 and is projected to reach USD 47,101.0 million by 2030, growing at a CAGR of 4.8% from 2025 to 2030. This growth is primarily driven by the rising prevalence of cardiovascular diseases such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Atrial Fibrillation (AF), which increase the demand for anticoagulant therapies to prevent serious health complications.

Significant advancements in anticoagulant formulations, coupled with growing utilization by healthcare professionals and the introduction of direct-acting oral anticoagulants (DOACs), have further fueled market expansion. These innovations provide safer, more convenient, and effective options for managing thromboembolic risks.

In recent years, there has been a notable rise in venous thromboembolism (VTE) cases worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), up to 900,000 individuals in the U.S. are affected by VTE annually, with approximately 60,000–100,000 fatalities occurring each year. Healthcare providers increasingly rely on anticoagulants to prevent thromboembolic events and associated complications, such as strokes, which further drives market demand.

The growing prevalence of cardiovascular disorders is strongly linked to sedentary lifestyles, increasing urbanization, changing dietary habits, and insufficient physical activity. VTE is also associated with multiple risk factors, including cancer, complex surgeries, and pregnancy. As one of the leading causes of preventable hospital deaths in the U.S., VTE underscores the critical role of anticoagulants in patient care. These factors collectively point to sustained growth in the adoption of anticoagulant therapies globally.

Key Market Trends & Insights:

• North America dominated the global anticoagulants market in 2024, accounting for a revenue share of 51.2%, driven by well-established healthcare infrastructure, high awareness of cardiovascular diseases, and widespread access to advanced anticoagulant therapies.

• Within the region, the U.S. led the market with a revenue share of 85.8% in 2024, reflecting the country’s large patient population, advanced clinical care facilities, and high adoption of innovative therapies for the prevention and management of thromboembolic disorders.

• By drug category, the Novel Oral Anticoagulants (NOACs) segment dominated globally with a revenue share of 57.2% in 2024, due to their convenience, safety profile, and growing preference over traditional anticoagulants for stroke and VTE prevention.

• By route of administration, the oral anticoagulants segment held the largest revenue share, driven by ease of use, improved patient compliance, and reduced need for frequent hospital visits compared to injectable therapies.

• By application, the Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment led the global anticoagulants market in 2024, highlighting the high prevalence of cardiovascular disorders and the critical role of anticoagulant therapies in preventing strokes, heart attacks, and related complications.

Order a free sample PDF of the Anticoagulants Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 35,957.0 Million

• 2030 Projected Market Size: USD 47,101.0 Million

• CAGR (2025-2030): 4.8%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Some of the key companies operating in the global anticoagulants industry include Aspen Holdings, Pfizer Inc., Sanofi, Bristol-Myers Squibb Company, Bayer AG, and several others. Leading market participants are actively implementing strategies such as new product development, innovation-driven product launches, increased investment in research and development, and strategic collaborations with other organizations to strengthen their competitive positions and expand global market presence.

Aspen Holdings is a pharmaceutical company specializing in the marketing and manufacturing of a broad portfolio of post-patent and branded medicines. Its product offerings include injectables, prescription drugs, and over-the-counter (OTC) medicines, with several anticoagulant-related products such as Arixtra, Fraxiparine, and Fraxodi designed to prevent and treat thrombotic conditions.

Pfizer Inc., a leading global biopharmaceutical company, provides a wide range of anticoagulation therapies, including the novel oral anticoagulant (NOAC) Eliquis (apixaban). In addition, the company offers Heparin Sodium Injection in multiple formats, including IV bags, vials, and prefilled syringes, catering to diverse clinical settings and patient needs. These products reflect Pfizer’s focus on innovation, safety, and improving patient outcomes in the prevention and management of thromboembolic disorders.

Key Players

• Aspen Holdings

• Pfizer Inc.

• Bristol-Myers Squibb Company

• GSK plc

• Sanofi

• Bayer AG

• Boehringer Ingelheim International GmbH

• DAIICHI SANKYO COMPANY, LIMITED

• Johnson & Johnson Services, Inc.

• Eisai Co., Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global anticoagulants market is expected to experience steady growth, driven by the rising prevalence of cardiovascular diseases and thromboembolic conditions worldwide. Increasing adoption of novel oral anticoagulants (NOACs) and oral administration is accelerating market expansion due to their convenience, improved safety profile, and enhanced patient compliance. Traditional anticoagulants, such as heparin, continue to play a vital role, particularly in resource-limited settings. While developed regions dominate the market, emerging regions are witnessing growth due to increasing cardiovascular disease burden, aging populations, and improved access to healthcare.